Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

336.70
+16.335.10%
Volume:433.88K
Turnover:146.47M
Market Cap:40.07B
PE:575.84
High:340.81
Open:329.29
Low:328.75
Close:320.37
52wk High:385.22
52wk Low:174.74
Shares:119.00M
Float Shares:75.64M
Volume Ratio:1.43
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5847
EPS(LYR):-6.1240
ROE:1.81%
ROA:1.69%
PB:9.70
PE(LYR):-54.98

Loading ...

Beone Medicines : RBC Raises Target Price to $417 From $408

THOMSON REUTERS
·
Jan 08

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Benzinga_recent_news
·
Jan 08

BEIGENE (06160) Awards Total of 53,300 Restricted Stock Units in American Depositary Shares

Stock News
·
Jan 07

BEIGENE's BCL-2 Inhibitor "Sotokela" Approved for Market Launch

Deep News
·
Jan 05

BeOne Medicines Says US FDA's Fast Track Designation Received for Hepatocellular Carcinoma Treatment

MT Newswires Live
·
Dec 18, 2025

Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE

Deep News
·
Dec 15, 2025

BeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says

MT Newswires Live
·
Dec 11, 2025

BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features

Benzinga_recent_news
·
Dec 08, 2025

BEIGENE (06160) Grants a Total of 21,300 Restricted Share Units

Stock News
·
Dec 04, 2025

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Key Economic Data Deluge

MT Newswires Live
·
Nov 26, 2025

BeOne Medicines (ONC): Assessing Valuation Following Recent Share Price Momentum

Simply Wall St.
·
Nov 26, 2025

BeOne Medicines Lymphoma Drug Gets FDA Priority Review

Dow Jones
·
Nov 26, 2025

BeOne Medicines says FDA grants Priority Review to NDA for sonrotoclax

TIPRANKS
·
Nov 26, 2025

Jefferies Sticks to Its Buy Rating for BeOne Medicines (ONC)

TIPRANKS
·
Nov 25, 2025

BeOne Medicines (ONC) Is Up After ZIIHERA Phase 3 Trial Shows Strong Efficacy for HER2-Positive Cancer

Simply Wall St.
·
Nov 25, 2025

BeOne Medicines Initiated at Buy by Truist Securities

Dow Jones
·
Nov 25, 2025

BeOne Medicines initiated with a Buy at Truist

TIPRANKS
·
Nov 24, 2025

Beone Medicines : Truist Securities Initiates Coverage With Buy Rating; Target Price $400

THOMSON REUTERS
·
Nov 24, 2025

BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains "Buy" Rating

Deep News
·
Nov 18, 2025

HK Stock Movement | BEIGENE (06160) Opens Over 3% Higher as Phase 3 Clinical Study of Zanidatamab Combined with Tislelizumab and Chemotherapy Shows Positive Results

Stock News
·
Nov 18, 2025